GI-108

PreclinicalSmall molecule

GGI Innovation, Inc.

GI-108 is one of 73 small molecule programs targeting Solid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Advanced or Metastatic Solid TumorsRecruiting

Solid TumorPreclinical

Recruiting

Advanced or Metastatic Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

DATROWAY

Daiichi Sankyo

Preclinical

1 3

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

Navmi

SSummit Therapeutics

Preclinical

1 5

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 6

Soc

Pfizer

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 8

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

2 9

Sacituzumab Govitecan-Hziy

Gilead

Preclinical

1 10

SAR445877

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Solid Tumor

NCT07172802

Clinical

Trials by Indication[1]

Solid Tumor1 trial

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as a Single Agent in Patients With Advanced or Metastatic Solid Tumors

Recruiting·GGI Innovation, Inc.·Preclinical·NCT07172802·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GI-108. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GI-108 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GI-108. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GI Innovation, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGI Innovation, Inc.

GI-108

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News